ARCHIVES

In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List

This article is from The Cancer Letter archive.

Vol. 09 No. 46 | December 2, 1983

Download PDF Visit The Full Archive

Related Articles

Full Text Of NCI-Specific Language In House Report

July 31, 1992

Guest Editorial: Richard Schilsky Reflects On His Past Decade WithThe Board of Scientific Advisors

June 24, 2011

NIH To Fund Fewer Grants This Year, But Reduce Cuts to Individual Awards.

February 8, 2008

CHOP Gets Concept Approval; DCT Release RFAs for Lung, Colon Drug Discovery Groups

October 24, 1986

Study: Routine CT Not Needed In Detecting DLBCL Remissions

May 31, 2013

Oncology Groups Oppose Proposed Cuts In Medicare Payments For Cancer Drugs

October 11, 2002